Laser photocoagulation for proliferative diabetic retinopathy. by Evans, Jennifer R et al.
Evans, JR; Michelessi, M; Virgili, G (2014) Laser photocoagulation
for proliferative diabetic retinopathy. Cochrane Database Syst Rev,
11. CD011234. ISSN 1469-493X DOI: 10.1002/14651858.CD011234.pub2
Downloaded from: http://researchonline.lshtm.ac.uk/2030931/
DOI: 10.1002/14651858.CD011234.pub2
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Cochrane Database of Systematic Reviews
Laser photocoagulation for proliferative diabetic retinopathy
(Review)
Evans JR, Michelessi M, Virgili G
Evans JR, Michelessi M, Virgili G.
Laser photocoagulation for proliferative diabetic retinopathy.
Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD011234.
DOI: 10.1002/14651858.CD011234.pub2.
www.cochranelibrary.com
Laser photocoagulation for proliferative diabetic retinopathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
17DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Laser photocoagulation versus control, Outcome 1 Loss of 15 or more letters BCVA at 12
months. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Analysis 1.2. Comparison 1 Laser photocoagulation versus control, Outcome 2 Loss of 15 or more letters BCVA at 2
years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 1.3. Comparison 1 Laser photocoagulation versus control, Outcome 3 Loss of 15 or more letters BCVA at 3
years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 1.4. Comparison 1 Laser photocoagulation versus control, Outcome 4 Severe visual loss (BCVA < 6/60). . 45
Analysis 1.5. Comparison 1 Laser photocoagulation versus control, Outcome 5 Progression of diabetic retinopathy. . 46
Analysis 1.6. Comparison 1 Laser photocoagulation versus control, Outcome 6 Vitreous haemorrhage. . . . . . 47
47ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
48APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
53INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iLaser photocoagulation for proliferative diabetic retinopathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Laser photocoagulation for proliferative diabetic retinopathy
Jennifer R Evans1, Manuele Michelessi2, Gianni Virgili3
1CochraneEyes andVisionGroup, ICEH,LondonSchool ofHygiene&TropicalMedicine, London,UK. 2Ophthalmology, Fondazione
G.B. Bietti per lo studio e la ricerca in Oftalmolologia-IRCCS, Rome, Italy. 3Department of Translational Surgery and Medicine, Eye
Clinic, University of Florence, Florence, Italy
Contact address: Jennifer R Evans, Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical Medicine, Keppel
Street, London, WC1E 7HT, UK. jennifer.evans@lshtm.ac.uk.
Editorial group: Cochrane Eyes and Vision Group.
Publication status and date: New, published in Issue 11, 2014.
Review content assessed as up-to-date: 3 June 2014.
Citation: Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database of
Systematic Reviews 2014, Issue 11. Art. No.: CD011234. DOI: 10.1002/14651858.CD011234.pub2.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Diabetic retinopathy is a complication of diabetes in which high blood sugar levels damage the blood vessels in the retina. Sometimes
new blood vessels grow in the retina, and these can have harmful effects; this is known as proliferative diabetic retinopathy. Laser
photocoagulation is an intervention that is commonly used to treat diabetic retinopathy, in which light energy is applied to the retina
with the aim of stopping the growth and development of new blood vessels, and thereby preserving vision.
Objectives
To assess the effects of laser photocoagulation for diabetic retinopathy compared to no treatment or deferred treatment.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 5), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
June 2014), EMBASE (January 1980 to June 2014), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com),
ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 3 June 2014.
Selection criteria
We included randomised controlled trials (RCTs) where people (or eyes) with diabetic retinopathy were randomly allocated to laser
photocoagulation or no treatment or deferred treatment. We excluded trials of lasers that are no longer in routine use. Our primary
outcome was the proportion of people who lost 15 or more letters (3 lines) of best-corrected visual acuity (BCVA) as measured on a
logMAR chart at 12 months. We also looked at longer-term follow-up of the primary outcome at two to five years. Secondary outcomes
included mean best corrected distance visual acuity, severe visual loss, mean near visual acuity, progression of diabetic retinopathy,
quality of life, pain, loss of driving licence, vitreous haemorrhage and retinal detachment.
Data collection and analysis
We used standard methods as expected by the Cochrane Collaboration. Two review authors selected studies and extracted data.
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Main results
We identified a large number of trials of laser photocoagulation of diabetic retinopathy (n = 83) but only five of these studies were eligible
for inclusion in the review, i.e. they compared laser photocoagulation with currently available lasers to no (or deferred) treatment. Three
studies were conducted in the USA, one study in the UK and one study in Japan. A total of 4786 people (9503 eyes) were included in
these studies. The majority of participants in four of these trials were people with proliferative diabetic retinopathy; one trial recruited
mainly people with non-proliferative retinopathy. Four of the studies evaluated panretinal photocoagulation with argon laser and one
study investigated selective photocoagulation of non-perfusion areas. Three studies compared laser treatment to no treatment and two
studies compared laser treatment to deferred laser treatment. All studies were at risk of performance bias because the treatment and
control were different and no study attempted to produce a sham treatment. Three studies were considered to be at risk of attrition
bias.
At 12 months there was little difference between eyes that received laser photocoagulation and those allocated to no treatment (or
deferred treatment), in terms of loss of 15 or more letters of visual acuity (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.89 to
1.11; 8926 eyes; 2 RCTs, low quality evidence). Longer term follow-up did not show a consistent pattern, but one study found a 20%
reduction in risk of loss of 15 or more letters of visual acuity at five years with laser treatment. Treatment with laser reduced the risk of
severe visual loss by over 50% at 12 months (RR 0.46, 95% CI 0.24 to 0.86; 9276 eyes; 4 RCTs, moderate quality evidence). There
was a beneficial effect on progression of diabetic retinopathy with treated eyes experiencing a 50% reduction in risk of progression
of diabetic retinopathy (RR 0.49, 95% CI 0.37 to 0.64; 8331 eyes; 4 RCTs, low quality evidence) and a similar reduction in risk of
vitreous haemorrhage (RR 0.56, 95% CI 0.37 to 0.85; 224 eyes; 2 RCTs, low quality evidence).
None of the studies reported near visual acuity or patient-relevant outcomes such as quality of life, pain, loss of driving licence or
adverse effects such as retinal detachment.
We did not plan any subgroup analyses, but there was a difference in baseline risk in participants with non-proliferative retinopathy
compared to those with proliferative retinopathy. With the small number of included studies we could not do a formal subgroup
analysis comparing effect in proliferative and non-proliferative retinopathy.
Authors’ conclusions
This review provides evidence that laser photocoagulation is beneficial in treating proliferative diabetic retinopathy. We judged the
evidence to be moderate or low, depending on the outcome. This is partly related to reporting of trials conducted many years ago, after
which panretinal photocoagulation has become the mainstay of treatment of proliferative diabetic retinopathy.
Future Cochrane Reviews on variations in the laser treatment protocol are planned. Future research on laser photocoagulation should
investigate the combination of laser photocoagulation with newer treatments such as anti-vascular endothelial growth factors (anti-
VEGFs).
P L A I N L A N G U A G E S U M M A R Y
Laser photocoagulation for proliferative diabetic retinopathy
Review question
Is laser photocoagulation an effective treatment for diabetic retinopathy?
Background
Diabetic retinopathy (DR) is a common problem for people with diabetes and can lead to loss of vision. The back of the eye (retina)
can develop problems because of diabetes, including the growth of harmful new blood vessels (proliferative DR, referred to here as
’PDR’). Laser photocoagulation is a commonly used treatment for DR in which the eye doctor uses a laser on the back of the eye to
stop some of the harmful changes.
Study characteristics
We found five studies. The searches were done in April 2014. Three studies were done in the USA, one study in the UK and one study
in Japan. A total of 4786 people (9503 eyes) were included in these studies. Most participants had PDR.
Key results
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We found that moderate vision loss at 12 months was similar in eyes treated with laser and eyes that were not treated, but similar
assessments made at a later date showed that eyes treated with laser were less likely to have suffered moderate vision loss. Treatment
with laser reduced the risk of severe visual loss by over 50% at 12 months. There was a similar effect on the progression of DR. None
of the studies reported patient-relevant outcomes such as pain or loss of driving licence.
Quality of the evidence
We did not find very many studies and those we found were done quite a long time ago when standards of trial conduct and reporting
were lower. We judged the quality of the evidence to be low, with the exception of the results for severe visual loss, which we judged to
be moderate quality evidence.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Laser photocoagulation compared to no treatment (or deferred treatment) for diabetic retinopathy
Patient or population: people with diabetic retinopathy
Settings: Ophthalmology clinics
Intervention: laser photocoagulation
Comparison: no treatment or deferred treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* Corresponding risk
No treatment or deferred
treatment
Laser photocoagulation
Loss of 15 or more letters
BCVA
Follow-up: 12 months
Low risk (non-proliferative DR) RR 0.99
(0.89 to 1.11)
8926
(2 RCTs)
⊕⊕©©
LOW 1,2
The pooled RR 0.99 (0.89
to 1.11) is derived from
one study with mainly low
risk population RR 1.07
(0.92 to 1.23) and one
study with mainly high
risk population 0.86 (0.71
to 1.04)
100 per 1000 99 per 1000
(89 to 111)
High risk (proliferative DR)
250 per 1000 248 per 1000
(223 to 278)
BCVA measured using
logMAR acuity (0 = 6/6
visual acuity, higher score
is worse visual acuity)
Follow-up: 12 months
The mean BCVA at 12
months in the control
group was 0.12 logMAR
The mean BCVA at 12
months in the intervention
group was 0.02 logMAR
units higher (worse; 0.23
lower to 0.27 higher)
36
(1 RCT)
⊕⊕©©
LOW 1,3
Severe visual loss (BCVA
<6/60)
Follow-up: 12 months
Low risk (non-proliferative DR) RR 0.46
(0.24 to 0.86)
9276
(4 RCTs)
⊕⊕⊕©
MODERATE 1,4
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10 per 1000 5 per 1000
(2 to 9)
High risk (proliferative DR)
50 per 1000 23 per 1000
(12 to 43)
Progression of diabetic
retinopathy
Follow-up: 12 months
Low risk (non-proliferative DR) RR 0.49
(0.37 to 0.64)
8331
(4 RCTs)
⊕⊕©©
LOW 1,5
100 per 1000 49 per 1000
(37 to 64)
High risk (proliferative DR)
400 per 1000 196 per 1000
(148 to 256)
Quality of life
Follow-up: 12 months
See comment See comment No studies reported this
outcome
Pain
Follow-up: at time of
treatment
See comment See comment No studies reported this
outcome
Loss of driving licence
Follow-up: within three
months of treatment
See comment See comment No studies reported this
outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; DR: diabetic retinopathy; BCVA: Best corrected visual acuity
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GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
*Estimates of assumed risk are indicative only, as estimates at 12 months were not available in all studies. For the low risk populations
they were estimated from ETDRS (but acknowledging that the control group received deferred laser) and for the high risk populations
they were estimated from DRS and Hercules 1977.
1Downgraded for risk of bias (-1): studies were not masked and treatment groups different
2Downgraded for inconsistency (-1): I2 = 69% and effect estimates were in different directions. See comments for details
3Downgraded for imprecision (-1): wide confidence intervals
4 There was heterogeneity (I2 = 70%) but all effect estimates favoured laser photocoagulation so we did not downgrade for inconsistency
5Downgraded for indirectness (-1): study results were reported at 1, 3, 4 and 5 years
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B A C K G R O U N D
Description of the condition
Diabetic retinopathy (DR) is a microvascular complication of di-
abetes in which high blood sugar levels damage the blood vessels
in the retina (Davidson 2007). These blood vessels may become
blocked, which leads to a reduction or cessation of blood supply to
the retina (non-proliferative diabetic retinopathy). Sometimes the
vessels swell up and leak fluid (macular oedema) and sometimes
new vessels grow (neovascularisation) on the retina and vitreous
(also called the vitreous humour); this is known as proliferative
diabetic retinopathy (PDR).
In general, the early stages of the disease are not associated with
any symptoms. Disease progression is associated with visual loss
and blindness, if left untreated. DR is an important cause of vi-
sual impairment worldwide. An estimated 285 million people are
visually impaired and of these approximately 39 million people
are blind (Pascolini 2012). DR is believed to account for approx-
imately 1% of visual impairment and blindness, meaning nearly
three million people worldwide are visually impaired due to this
condition. The total number of people with diabetes is projected
to increase from 171 million people in 2000 to 366 million in
2030 (Wild 2004).
This Cochrane Review is concerned with the treatment of DR,
both proliferative and non-proliferative, but not macular oedema
which is addressed in another review (Jorge 2013).
Description of the intervention
Laser photocoagulation involves applying light energy to the
retina. This is absorbed by the retinal pigments, which heat up and
cause thermal damage to the retinal tissues. There are several types
of laser: gas (argon, krypton), diode, dye and YAG (RCOphth
2012).
Type of laser Wavelength in nm (colour) Comments
Argon 488 (blue) 514 (green) -
Krypton 568 (yellow) 647 (red) -
Dye laser 570 to 630, 577 (yellow) often used -
Diode laser 810 (infrared) Micropulse mode available
Frequency-doubled yttrium aluminium
garnet (YAG) laser
532 (green) often used Pattern scan laser (PASCAL) often used
Laser application may focus on microaneurysms or be delivered
in a grid-pattern around the centre of the macula in people with
diabetic macular oedema (DMO). When delivered to the periph-
eral retina, it may be focal, directed to neovascular tufts, or more
commonly scattered, which is also known as panretinal photoco-
agulation (PRP) and in which 1200 to 2000 burns are applied to
the peripheral retina. Laser photocoagulation may be applied in
one session or may be delivered over several sessions to reduce the
risk of adverse effects.
Peripheral or panretinal laser treatment is commonly delivered to
ischaemic areas (i.e. those with low oxygen levels) in the retinal
periphery, with the aims of causing regression of retinal neovas-
cularisation and prevention of visual loss due to vitreous haem-
orrhage, tractional retinal detachment, or neovascular glaucoma,
which are the main causes of visual loss in patients with end-stage
PDR. Panretinal peripheral laser treatment was also initially pro-
posed as a treatment that might prevent the occurrence of PDR.
How the intervention might work
The aim of laser photocoagulation is to slow down the growth of
new blood vessels in the retina and thereby prevent the progression
of visual loss (Ockrim 2010). Focal laser photocoagulation uses
the heat of light to seal or destroy abnormal blood vessels in the
retina. Individual vessels are treated with a small number of laser
burns.
PRP aims to slow down the growth of new blood vessels in a wider
area of the retina. Many hundreds of laser burns are placed on the
peripheral parts of the retina to stop blood vessels from growing
(RCOphth 2012). It is thought that the anatomic and functional
changes that result from photocoagulation may improve the oxy-
gen supply to the retina, and so reduce the stimulus for neovas-
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cularisation (Stefansson 2001). Again the exact mechanisms are
unclear, but it is possible that the decreased area of retinal tissue
leads to improved oxygenation and a reduction in the levels of anti-
vascular endothelial growth factor. A reduction in levels of anti-
vascular endothelial growth factor may be important in reducing
the risk of harmful new vessels forming.
Why it is important to do this review
Laser photocoagulation is a well-established common treatment
for DR and there are many different potential strategies for de-
livery of laser treatment that are likely to have different effects. A
systematic review of the evidence for laser photocoagulation will
provide important information on benefits and harms to guide
treatment choices. With the advent of new treatments, especially
the anti-vascular endothelial growth factor (anti-VEGF) agents,
laser photocoagulation may become less commonly used in higher
income countries, but may still have relevance as a potentially cost-
effective treatment in other parts of the world. This review should
be read in conjunction with related Cochrane Reviews of treat-
ment of DR, including laser photocoagulation for diabetic macu-
lar oedema (Jorge 2013), anti-VEGF for proliferative retinopathy
(Martinez-Zapata 2014), anti-VEGF for diabetic macular oedema
(Virgili 2012), and steroids for diabetic macular oedema (Grover
2008).
This is the first in a series of planned reviews on laser photocoag-
ulation. Future reviews will compare different photocoagulation
techniques.
O B J E C T I V E S
Toassess the effects of laser photocoagulation for diabetic retinopa-
thy compared to no treatment or deferred treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) irrespective of
the language in which they were published, or publication status
(published or unpublished).
Types of participants
People with pre-proliferative (DR) or proliferative diabetic
retinopathy (PDR). We excluded trials where the primary aim was
to treat diabetic macular oedema as this is covered in a separate
Cochrane Review (Jorge 2013).
Types of interventions
We considered trials of peripheral laser photocoagulation with any
ophthalmic laser at any wavelength, either focal or panretinal.
We compared this to no treatment, sham treatment or deferred
treatment.
We included studies using any type of laser, but not studies using
xenon arc photocoagulation or ruby laser, since these lasers have
not been used for decades because of an observed increase in the
risk of side-effects, such as peripheral field damage and macular
traction (DRS 1981).
We excluded trials that compared different types (wavelength) of
laser, laser application at different powers or for different exposure
times, and trials that compared different regimens for the appli-
cation of the laser (e.g. compared the number, pattern or location
of burns, or compared different numbers of treatment sessions) as
these will be considered in future Cochrane Reviews.
This review should be read in conjunction with related Cochrane
Reviews that address the comparison between laser photocoagu-
lation and other treatments such as anti-VEGF (Martinez-Zapata
2014; Virgili 2012), and steroids (Grover 2008).
Types of outcome measures
Primary outcomes
• Proportion of people who lose 15 or more letters (3 lines) of
best-corrected visual acuity (BCVA) as measured on a logMAR
chart.
Secondary outcomes
1. Mean distance visual acuity (BCVA).
2. Mean near visual acuity (NVA).
3. Severe visual loss (BCVA < 6/60).
4. Progression of diabetic retinopathy, as defined by trial
investigators.
5. Quality of life measured using any validated questionnaire.
6. Adverse events: pain, loss of driving licence, vitreous
haemorrhage, retinal detachment.
With the exception of adverse events, we aimed to collect data on
these outcomes at one year after initiation of treatment, which we
defined as the period between six and 18 months. We considered
adverse events at any time point, but these are most likely to occur
within three months of treatment. We also planned to report the
primary outcome at longer time periods - two to five years - in
order to comment on whether any effects observed are sustained
in the long term.
We made some amendments to the outcomes from the protocol.
See Differences between protocol and review.
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Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Group Trials Register) (2014, Issue 5), Ovid MED-
LINE, Ovid MEDLINE In-Process and Other Non-Indexed Ci-
tations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January
1946 to June 2014), EMBASE (January 1980 to June 2014),
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the
World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We
did not use any date or language restrictions in the electronic
searches for trials. We last searched the electronic databases on 3
June 2014.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), mRCT (Appendix 4), ClinicalTrials.gov (Appendix 5) and the
ICTRP (Appendix 6).
Searching other resources
We searched the reference lists of included studies and other re-
views identified by the searches.
Data collection and analysis
Selection of studies
Two review authors (JE, MM) independently screened the search
results and selected trials for inclusion. We resolved disagreements
through discussion.
We screened the list of citations and abstracts and classified records
into ’possibly relevant’ and ’definitely not relevant’. For the records
we identified as ’possibly relevant’ we obtained the full-text arti-
cles. Following the Criteria for considering studies for this review
we classified trials into ’to be included’ or ’to be excluded’. We
documented excluded trials in the category in the Characteristics
of excluded studies section.
Data extraction and management
Two authors (JE,MM) independently extracted data from trial re-
ports and entered the data into Review Manager (RevMan 2014).
We resolved any differences in opinion through discussion. We
used a data collection spreadsheet. We obtained English transla-
tions of any trial reported in a language other than English before
extracting data.
We collected data on trial characteristics as detailed in Appendix
7.
We obtained the following data on outcomes specified in Types of
outcome measures: for dichotomous outcomes, we collected data
on the number of events and total participants followed up in each
trial arm; for continuous outcomes, we collected data on the mean
and standard deviation in each trial arm.
We did not attempt to obtain further information from trialists.
Assessment of risk of bias in included studies
We assessed risk of bias using theCochraneCollaboration’s tool for
assessing the risk of bias as described in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Measures of treatment effect
We calculated the risk ratio (RR) for all dichotomous variables.
This was a variation on the protocol - see Differences between
protocol and review.
For continuous variables (only data on distance visual acuity were
available) we calculated the mean difference.
All measures of effectwere reported with 95% confidence intervals
(CIs).
Unit of analysis issues
Four of the five studies were within-person studies but were re-
ported as unmatched. We have used these data as reported, which
is a conservative analysis. One trial considered one eye per person
only, but it was not clear how that eye was selected for inclusion
in the trial.
Dealing with missing data
We documented follow-up by intervention group. We aimed to
collect data on reasons for loss to follow-up, but this information
was not usually available. We documented when loss to follow-up
was high (over 20%), or unbalanced between treatment groups,
as a potential source of attrition bias. We planned to conduct
an intention-to-treat (ITT) analysis if this was reported by the
trialists, but we have conducted an available case analysis because
the majority of trials did not report an ITT and the one small
trial that did only reported one outcome as an ITT analysis (Sato
2012). An available case analysis makes the assumption that the
treatment effect in people lost to follow-up was the same as that
in people who were observed (assessed).
Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the forest plots
and by calculating the I2 value (Higgins 2002).We also considered
the Chi2 test for heterogeneity, but this may have low power as
few trials met the inclusion criteria.
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Assessment of reporting biases
We were unable to look at small trial effects as we had planned
because there were only five included trials.
We considered selective outcome reporting bias as part of the as-
sessment of risk of bias in the individual studies (see Assessment
of risk of bias in included studies section).
Data synthesis
We pooled data using a random-effects model, unless there were
three or fewer trials, in which case we used a fixed-effect model.
There was considerable heterogeneity, and for many analyses the I
2 statistic was over 50%. In most analyses all effect estimates were
in the same direction and we report a pooled value. The exception
was Analysis 1.1, but as the effect estimates were relatively close
to 1 we have reported a pooled estimate. This is a variation from
our protocol - see Differences between protocol and review.
Subgroup analysis and investigation of heterogeneity
We did not plan any subgroup analysis at the protocol stage,
but there was considerable heterogeneity in terms of baseline risk
in participants with non-proliferative retinopathy and those with
proliferative retinopathy.
There was not enough evidence to do subgroup analysis based on
these groups, and new trials in future are unlikely.
Sensitivity analysis
We planned to repeat the analyses excluding studies at high risk of
selection, or detection bias, or both. In most analyses trials were
similar with respect to these risk of bias domains and so a sensitivity
analysis was not possible. We did one sensitivity analysis for the
outcome progression of DR.
Summary of findings
We report absolute risks and measures of effect in a ’Summary of
findings’ table, providing an overall assessment of the quality of
the evidence for each outcome using the GRADE system (Guyatt
2011). Two review authors (JE, GV) independently performed
the GRADE assessment.
Our pre-specified outcome measures were:
1. proportion of people who lose 15 or more letters (3 lines) of
BCVA as measured on a logMAR chart;
2. mean logMAR visual acuity;
3. averse event: loss of driving licence;
4. adverse event: severe visual loss (BCVA < 6/60);
5. adverse event: pain;
6. quality of life measured using a validated questionnaire.
We planned to report outcomes 1, 2 and 6 at one year, outcomes
3 and 4 within three months of treatment and outcome 5 at time
of treatment.
We modified the protocol to include severe visual loss as an effec-
tiveness outcome measured at one year. See Differences between
protocol and review.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 3517 references (Figure
1). TheTrials SearchCo-ordinator removed 545 duplicate records,
screened the remaining 2972 records and removed 2660 references
that were not relevant to the scope of the review. We screened a
total of 312 references and discarded 173 reports as these were
not relevant to the scope of the review. We reviewed 139 full-text
reports and included 30 reports of five studies that were eligible
for inclusion in the review. We were unable to assess 13 reports,
either because the full-text copy was unavailable or because a trans-
lation was needed. These reports are listed in the Studies awaiting
classification section, but are unlikely to be eligible trials. We also
excluded 96 reports that referred to 78 trials, see Characteristics
of excluded studies for details.
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Figure 1. Results from searching for studies for inclusion in the review
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Included studies
We identified five studies that compared laser photocoagulation
to a control. Three studies were conducted in the USA (DRS
1978; ETDRS 1991; Yassur 1980), one study in theUK (Hercules
1977), and one study in Japan (Sato 2012).
Four studies were within-person RCTs i.e. one eye was randomly
allocated to laser photocoagulation and the other eye to the control
(DRS 1978; ETDRS 1991; Hercules 1977; Yassur 1980). Sato
2012 randomly allocated people to treatment and only one eye
was included in the study; it was unclear how the eye was selected.
The number of participants enrolled ranged from 45 in Yassur
1980 to 3711 in ETDRS 1991. The average age of participants
ranged from 41 years in Hercules 1977 to 60 years in Sato 2012.
Most studies recruited participants aged approximately 18 to 70
years with an average age of around 45 years. The percentage of
women enrolled ranged from 25% in Sato 2012 to 48% in Yassur
1980, but on average between 40% and 45% of the participants
in each trial were women.
Two studies enrolled people with PDR only (Hercules 1977;
Yassur 1980); two studies enrolled people either with moderate
or severe non-proliferative DR or PDR (DRS 1978; ETDRS
1991); and one study enrolled participants with pre-proliferative
DR (Sato 2012). In the DRS 1978 study approximately 80% of
participants had PDR; in the ETDRS 1991 study approximately
20% of participants had PDR.
Most studies used PRP with argon laser (Table 1). The exception
was Sato 2012,which evaluated selective photocoagulationof non-
perfusion areas. Three studies compared laser to no treatment
(DRS 1978; Hercules 1977; Yassur 1980); two studies compared
laser to deferred laser treatment (ETDRS 1991; Sato 2012; i.e.
control participants received laser when severe non-proliferative
(ETDRS 1991) or PDR (ETDRS 1991; Sato 2012) developed).
Excluded studies
See Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Generation of the allocation sequence was considered adequate in
two trials (DRS 1978; Sato 2012) and was not clearly described
in the rest. As most of the studies were within-person studies,
allocation concealment was not judged to be a problem (as all
participants received both intervention and control). In the one
parallel group study the allocationwas clearly described and judged
to be at low risk of bias (Sato 2012).
Blinding
We judged the studies that measured and reported visual acuity to
be at a high risk of bias because the treatment and control groups
were obviously different and patient knowledge of intervention
could affect themeasurement of visual acuity. However, the extent
of the bias is difficult to judge, and some studies had specific
protocols to improve the accuracy of the measurement of vision,
such as encouraging patients to read as far down the chart as
possible (DRS 1978). In general, we judged that patient and carer
knowledge of assignment would not affect the progression of DR.
Incomplete outcome data
We judged within-person studies to be at low risk of attrition bias
by definition because, although there may be attrition in patient
follow-up, the follow-upbetween intervention and control groups,
i.e. between eyes, will always be equal. However, two studies selec-
tively removed participants who received treatment in the control
eye (Hercules 1977; Yassur 1980), which we considered to be a
potential source of bias for the effect estimate. The one parallel
group study had considerable loss to follow-up (Sato 2012).
Selective reporting
In general reporting bias was difficult to judge with the informa-
tion available. None of the studies reported all our review out-
comes.
Other potential sources of bias
The Sato 2012 study was stopped early.
Effects of interventions
See: Summary of findings for the main comparison Laser
photocoagulation compared to control for diabetic retinopathy
1.1 Loss of 15 or more letters BCVA at 12 months
For this outcomewe found two relevant trials (DRS 1978; ETDRS
1991: n = 8926; Figure 3; Analysis 1.1). One of these studies re-
ported loss of 10 or more letters rather than loss of 15 or more
letters (DRS 1978). There was considerable heterogeneity of effect
(I2 = 69%; P value = 0.07). In the DRS 1978 study fewer eyes
given laser photocoagulation lost 10 or more letters compared to
untreated eyes, but there was uncertainty and the confidence in-
tervals included 1 (RR 0.86, 95%CI 0.71 to 1.04). In the ETDRS
1991 study more eyes treated with laser photocoagulation lost 15
or more letters over 12 months compared to eyes given deferred
treatment, but again there was uncertainty and the confidence in-
tervals included 1 (RR 1.07, 95% CI 0.92 to 1.23).
Figure 3. Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.1 Loss of 15 or
more letters BCVA at 12 months
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1.2 Loss of 15 or more letters BCVA at longer follow-
up times
Two trials reported this outcome at two years (DRS 1978; ETDRS
1991: n = 8306; Analysis 1.2). Fewer eyes given laser photocoag-
ulation lost 15 (or 10) or more lines of visual acuity at two years
compared to untreated (DRS 1978), or deferred treatment eyes
(ETDRS 1991; RR 0.88, 95% CI 0.80 to 0.97). There was con-
siderable heterogeneity I2 = 73%, P value = 0.06). However, as
both effect estimates were in the same direction (0.74 and 0.92)
we have reported a pooled estimate.
Two trials reported this outcome at three years (ETDRS 1991;
Sato 2012: n = 7458; Analysis 1.3). More eyes receiving laser pho-
tocoagulation lost 15 or more letters BCVA at three years com-
pared to eyes with deferred treatment, but there was uncertainty
in the result and the confidence intervals included 1 (RR 1.07,
95%CI 0.93 to 1.23). The results of the two trials were reasonably
consistent I2 = 14%.
No trials reported this outcome at four years.
One study reported this outcome at five years (ETDRS 1991; n =
7422). Eyes receiving laser photocoagulationwere less likely to lose
15 or more letters compared to eyes receiving deferred treatment
(RR 0.79, 95% CI 0.72 to 0.85).
1.3 Mean BCVA at 12 months
One study reported mean logMAR BCVA at three years (Sato
2012). The difference between the groups was small and uncertain
(MD 0.02, 95% CI -0.23 to 0.27; n = 36).
2 Mean NVA at 12 months
None of the studies reported near visual acuity.
3 Severe visual loss (BCVA < 6/60)
For the outcome of severe visual loss (BCVA < 6/60) we found
four relevant trials (DRS 1978; ETDRS 1991; Hercules 1977;
Sato 2012: n = 9276; Figure 4; Analysis 1.4). Eyes receiving laser
photocoagulation were less likely to experience severe visual loss
compared to untreated eyes or eyes that received deferred treat-
ment (RR 0.46, 95% CI 0.24 to 0.86). This outcome had high
levels of heterogeneity (I2 = 70%, P value = 0.02), but as all the
effect estimates were in the same direction we report a pooled es-
timate. Such heterogeneity seemed due to Hercules 1977, a small
study including only patients with proliferative retinopathy, which
recorded the largest benefit with laser.
Figure 4. Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.4 Severe visual
loss (BCVA < 6/60)
4 Progression of diabetic retinopathy
For the outcome of progression ofDRwe found four relevant trials
(DRS 1978; ETDRS 1991; Sato 2012; Yassur 1980: n = 8331;
Figure 5; Analysis 1.5).
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Figure 5. Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.5 Progression of
diabetic retinopathy
In the DRS 1978 study progression was based on grading of fun-
dus photographs. Eyes were graded for new vessels and severity
was graded by comparison with standard images. The following
categories were used and progression was defined as change of one
or more grades from no new vessels to moderate or severe NVD
(NVDmeans new vessels on or within 1 disc diameter of the optic
disc; NVE means new vessels elsewhere):
1. no new vessels;
2. mild NVE, no NVD;
3. moderate or severe NVE, no NVD;
4. mild NVD;
5. moderate or severe NVD.
In the ETDRS 1991 study progression was defined as the devel-
opment of ’high risk proliferative diabetic retinopathy’. This was
defined as PDR with high risk characteristics as defined by DRS
1978. These were new vessels on or within 1 disc diameter of
the optic disc worse than a standard photograph, with or with-
out vitreous or preretinal haemorrhage; or vitreous or preretinal
haemorrhage accompanied by new vessels, either NVD (less than
standard photograph) or NVE greater than or equal to a quarter
of the disc area.
In Sato 2012 progression was defined as the development of PDR,
i.e. the growth of new vessels (detected by ophthalmoscopy or
fluorescein angiography), or preretinal/vitreous haemorrhage.
Yassur 1980 considered only new vessels on or near the optic
disc. These were graded into five grades of severity based on the
number of involved disc quadrants, calibre of the new vessels,
density of neovascularisation (NVD) or fibrous proliferation at
the disc (FPD), total area of NVD or FPD proliferation, plane of
NVD or FPD proliferation, and fluorescein leakage from NVD.
Progression was defined as increase in severity of one or more
grades.
The time frames at which these outcomes were reported were
different - ranging from 12 months to five years, and these are
indicated on the figure.
DRwas less likely to progress in eyes that received laser photocoag-
ulation (RR 0.49, 95% CI 0.37 to 0.64). There was considerable
heterogeneity I2 = 63%, P value = 0.05) but all effect estimates
were in the same direction, so we report a pooled estimate.
5 Quality of life
None of the included studies reported quality of life.
6.1 Adverse events: pain
None of the included studies reported pain.
6.2 Adverse events: loss of driving licence
None of the included studies reported patient outcomes such as
loss of driving licence.
6.3 Adverse events: vitreous haemorrhage
For this outcome of vitreous haemorrhage we found two relevant
trials (Hercules 1977; Sato 2012: n = 224; Analysis 1.6). People
receiving laser photocoagulationwere less likely to develop vitreous
haemorrhage (RR 0.56, 95% CI 0.37 to 0.85; I2 = 0%).
6.4 Adverse events: retinal detachment
None of the studies reported retinal detachment by intervention
group.
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Sensitivity analysis
For Analysis 1.5 progression of diabetic retinopathy, exclusion of
two trials at high risk of selection or detection bias resulted in a
RR of 0.55 (95% CI 0.48 to 0.64; participants = 8183; studies
= 2; I2 = 41%; Sato 2012; Yassur 1980). This is not dissimilar
to the analysis of all four trials (RR 0.49, 95% CI 0.37 to 0.64;
participants = 8331; studies = 4; I2 = 63%).
D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison.
We identified five trials. In the majority of these studies (4 trials,
99% of all participants) the intervention was panretinal photoco-
agulation (PRP) using an argon laser. There were differences in
the patient population included in these studies. Two trials in-
cluded 94% of the participants in this review (DRS 1978; ETDRS
1991). These two studies were conducted in the US population
and were complementary: DRS 1978 assessed whether PRP is ef-
fective compared to no treatment in people mostly affected by
proliferative diabetic retinopathy (PDR); ETDRS 1991 assessed
whether earlier peripheral laser treatment of diabetic retinopathy
(DR) in its non-proliferative or early proliferative stage is benefi-
cial, compared to a strategy in which laser is used at a later stage,
in high-risk PDR. Thus, any benefit in ETDRS 1991 should have
been less than that seen in DRS 1978 as laser is also part of the
control strategy in the former. In most of the analyses the effects
observed in ETDRS 1991 were indeed lower than DRS 1978 but
not significantly so. Even though there was evidence for statistical
heterogeneity, effects were generally in the same direction, so we
pooled the results to obtain (approximate) overall estimates of ef-
fect.
At 12 months there was little difference between eyes receiving
laser photocoagulation and those allocated to no treatment (or
deferred treatment), in terms of loss of 15 or more letters of visual
acuity. Longer term follow-up did not show a consistent pattern,
but ETDRS 1991 reported a 20% reduction in risk of loss of 15
or more letters of visual acuity at five years.
Treatment with laser reduced the risk of severe visual loss by over
50% at 12 months.
There was a beneficial effect on progression of DR with treated
eyes experiencing a 50% reduction in risk of progression and a
similar reduction in risk of vitreous haemorrhage.
None of the studies reported near visual acuity, quality of life,
pain, or patient relevant outcomes such as loss of driving licence
or adverse effects such as retinal detachment.
Overall completeness and applicability of
evidence
Overall there is not a large amount of evidence from randomised
controlled trials (RCTs) on laser photocoagulation compared to
no treatment or deferred treatment. The evidence is dominated
by two large studies conducted in the US population (DRS 1978;
ETDRS 1991).
Reflecting the fact that the studies were conducted some time ago,
there was a lack of data reported for many of our current pre-
specified review outcomes, in particular patient-relevant outcomes
such as quality of life.
We did not consider lasers that are not commonly used today but
the treatment parameters used in the included trials were differ-
ent to those in current use, in particular, smaller size and shorter
duration burns are now used (RCOphth 2012).
Overall the evidence is applicable to people presenting with mod-
erate to severe pre-proliferative and PDR, however, the fact that
relatively few trials were identified, and that these were all con-
ducted some time ago in high-income countries leaves a lack of
evidence for lower- and middle-income countries and different
parts of the world. However, we have no reason to suppose that
the effectiveness of these treatments would be different in lower-
income countries.
The introduction of anti-vascular endothelial growth factor (anti-
VEGF) therapy for treating several chorioretinal vascular diseases
has made it possible to achieve a rapid, but transient, regression of
new vessels in PDR, especially to try to clear vitreous haemorrhage,
but also to limit side effects of PRP regarding the occurrence of
diabetic macular oedema in patients at risk. Moreover, anti-VEGF
therapy is sometimes used in preparation of vitrectomy - which
includes use of an endolaser - in advanced PDR. However, use of
anti-VEGF in PDRmay have adverse effects and requires multiple
treatments. Other Cochrane Reviews compare the effectiveness of
anti-VEGF and laser treatment for PDR (Martinez-Zapata 2014),
and diabetic macular oedema (Virgili 2012).
Quality of the evidence
Overall there is not a large amount of evidence from RCTs on
the effects of laser photocoagulation compared to no treatment
or deferred treatment. The evidence is dominated by two large
studies conducted in the US population (DRS 1978; ETDRS
1991). These two studies were generally judged to be at low or
unclear risk of bias, with the exception of inevitable unmasking of
patients due to differences between intervention and control.
Four of the studies were within-person (i.e. pair-matched), but
none of the studies reported the results taking into account the
matching. This means that the results will be conservative (con-
fidence intervals wider than if matching had been taken into ac-
count). One study reported that they had repeated the analyses
taking into account the pair-matching and that ignoring the pair-
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matching was indeed a conservative approach (ETDRS 1991).
Overall we judged the quality of the evidence to be moderate or
low (Summary of findings for the main comparison), reflecting
the fact that the studies contributing to the review were conducted
some time ago, when standards of trial conduct and reporting were
lower; heterogeneity was also present.
Potential biases in the review process
We followed standard methods expected by the Cochrane Collab-
oration. All changes from protocol are documented in Differences
between protocol and review.
Agreements and disagreements with other
studies or reviews
In current clinical guidelines, e.g. RCOphth 2012, PRP is rec-
ommended in high-risk PDR. The recommendation is that “as
retinopathy approaches the proliferative stage, laser scatter treatment
(PRP) should be increasingly considered to prevent progression to high
risk PDR” based on other factors such as patients’ compliance or
planned cataract surgery.
These recommendations need to be interpreted while considering
the risk of visual loss associated with different levels of severity
of DR, as well as the risk of progression. Since PRP reduces the
risk of severe visual loss, but not moderate visual loss that is more
related to diabetic maculopathy, most ophthalmologists judge that
there is little benefit in treating non-proliferative DR at low risk of
severe visual damage, as patients would incur the known adverse
effects of PRP, which, although mild, include pain and peripheral
visual field loss and transient DMO. The results of this review
would confirm this approach.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides evidence that laser photocoagulation is ben-
eficial in treating diabetic retinopathy. There was not enough evi-
dence to judge whether the effect of treatment is different in non-
proliferative and PDR, but based on the baseline risk of progres-
sion of the disease, and risk of visual loss, the current approach of
caution in treating non-proliferative DR with laser would appear
to be justified.
By current standards the quality of the evidence is not high, how-
ever, the effects on risk of progression and risk of severe visual loss
are reasonably large (50% relative risk reduction).
Implications for research
Future Cochrane Reviews will examine specific questions regard-
ing the treatment protocol for laser photocoagulation.
Future trials on laser photocoagulation should focus on the com-
bination with, and comparison to, newer interventions, such as
anti-vascular endothelial growth factor (anti-VEGF) treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
DRS 1978
Methods Within-person RCT; both eyes included in study, eyes received different treatments
Participants Country: USA
Number of participants (eyes): 867 (1734)
% women: 44%
Average age (range): 43 years (15-69)
Inclusion criteria:
• BCVA 20/100 or better in each eye
• PDR in at least one eye or severe non-proliferative DR in both eyes
Exclusion criteria:
• Unilateral aphakia
• One or both lenses removed within 3 months of initial visit
• Anticoagulant therapy that could not be discontinued during treatment
• High or low blood pressure
• Myocardial infarction within 6 months of initial visit
• Active tuberculosis or history of hemoptysis within 12 months of initial visit
Interventions Intervention (n= 867 eyes)
• argon laser
Comparator (n= 867 eyes)
• no treatment
This trial also considered xenon arc laser but this has not been considered in this review
Outcomes Primary outcome:
• visual acuity
Secondary outcomes:
• visual fields
• morphologic changes in the retina and vitreous
Follow-up: every 4 months for 5 years
Notes Date conducted: April 1972-September 1975
Sources of funding: NIH
Declaration of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “One eye of each patient was randomly as-
signed to immediate photocoagulation and
the other to follow-up without treatment . . .
” Page 583, report number 8
Further details of sequence generation are
on page 158 of report number 6
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DRS 1978 (Continued)
Allocation concealment (selection bias) Low risk “The sealed envelope containing the assigned
treatment was not to be opened in the clinic
until a final determination had been made
of the patient’s eligibility and the patient had
signed the consent form at the second initial
visit” Page 158, report number 6
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Patients and personnel will have known
which eye was treated
Blinding of participants and personnel
(performance bias)
Progression of diabetic retinopathy
Low risk We judged it unlikely that patient or
carer knowledge of treatment assignment
would impact on the progression of dia-
betic retinopathy
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “ . . . measurement of best corrected visual
acuity by examiners who did not know the
identify of the treated eye and who attempted
to reduce patient bias by urging the patient
to read as far down the chart as possible with
each eye, guessing at letters until more than
one line was missed”. Page 584, report num-
ber 8
Blinding of outcome assessment (detection
bias)
Progression of diabetic retinopathy
Unclear risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition in patients but not in unit of anal-
ysis (eyes)
Selective reporting (reporting bias) Unclear risk No access to protocol
Other bias Unclear risk -
ETDRS 1991
Methods Within-person RCT; both eyes included in study, eyes received different treatments
Participants Country:USA
Number of participants (eyes): 3711 (7422)
% women: 44%
Average age 48 years (estimated; range 18-70)
Inclusion criteria:
• aged 18-70 years
• DR in both eyes
• each eye either:
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ETDRS 1991 (Continued)
◦ no macular oedema, visual acuity 20/40 or better and moderate or severe
nonproliferative or early PDR, or
◦ macular oedema, visual acuity of 20/200 or better and mild, moderate or
severe nonproliferative or early PDR
Exclusion criteria:
Interventions Intervention (n = 3711 eyes)
• early argon laser
Comparator (n = 3711 eyes)
• deferred argon laser
For the intervention group, eyes were also randomly allocated to ’full’ or ’mild’ PRP. For
the comparator group, argon laser was applied if high risk PDR was detected
Outcomes Primary outcome:
• development of severe visual loss which was defined as visual acuity < 5/200 at
two consecutive follow-up visits. Follow-up visits were 4 months apart. Visual acuity
was measured using an ETDRS chart at a distance of 4 metres and at 1 metre if visual
acuity < 20/100
Secondary outcomes:
• visual fields
• colour vision
• severity of retinopathy and macular oedema
Follow-up: every 4 months for an unknown number of years
Notes Date conducted: April 1980 to June 1985
Sources of funding: NEI
Declaration of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The randomization schedules were designed
to provide balance in: . . . the number of right
and left eyes assigned to early photocoagula-
tion”. Page 746, report number 7
Allocation concealment (selection bias) Low risk “At the randomization visit, the Clinical
Center ophthalmologist and staff reviewed the
patient’s . . . eligibility. . . The sealed mailer
from the Coordinating Center containing the
description of the photocoagulation strategy .
. . was then opened.” Page 746, report num-
ber 7
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Treatments were quite different and pa-
tients’ perception of treatment may well
have affected assessment of visual acuity
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ETDRS 1991 (Continued)
Blinding of participants and personnel
(performance bias)
Progression of diabetic retinopathy
Low risk We judged it unlikely that patient or
carer knowledge of treatment assignment
would impact on the progression of dia-
betic retinopathy
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk “The protocol specified that visual acuity ex-
aminers be trained and certified, that they
be masked from treatment assignment; that
they follow standard procedures for encourag-
ing patients to make the maximum effort to
read as many letters as possible with each eye”.
Page 747, report number 7
Blinding of outcome assessment (detection
bias)
Progression of diabetic retinopathy
Unclear risk “Fundus Photograph Reading Center staff,
without knowledge of treatment assignments
and clinical data, followed a standardized
procedure to grade fundus photographs and
fluorescein angiograms for individual lesions
of diabetic retinopathy” Page 748, report
number 7
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition in patients but not in unit of anal-
ysis (eyes)
Selective reporting (reporting bias) Unclear risk No access to protocol
Other bias Unclear risk -
Hercules 1977
Methods Within-person RCT; botheyes included in study, eyes received different treatments
Participants Country: UK
Number of participants (eyes): 94 (188 eyes)
% women: 40%
Average age (range): 41 years (18-65)
Inclusion criteria:
• both eyes of participant were similarly affected by a proliferative diabetic process
involving the optic disc
• observable features of the retinopathy had to be within the same grade when each
eye was classified
• visual acuity at initial assessment did not differ by more than two lines on the
Snellen chart and was at least 6/24 in the worse eye
Exclusion criteria:
• 70 years or older
• life expectancy was possibly too short for subsequent assessments
• previous pituitary ablation
• either eye had received previous xenon arc photocoagulation
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Hercules 1977 (Continued)
• presence of intercurrent ocular disease
• visual acuity was adversely affected by opacities of the media and visual pathways,
making retinal photography and treatment unsatisfactory
• proliferation in the retina had reached the late cicatricial stage with localised
traction detachment
Interventions Intervention (n = 94)
• argon laser
Comparator (n = 94)
• no treatment
Outcomes Outcomes:
• visual acuity: BCVA
• appearance of the optic discs 6 months after treatment and yearly from that point
(colour photographs and fluorescein angiograms)
• vitreous haemorrhage and other complications including uveitis, glaucoma, and
retinal detachment
• blindness: PDR and/or vitreous haemorrhage involving reduction in visual acuity
to less than 6/60 on the Snellen chart on at least two consecutive visits
Follow-up: 6 months
Notes Date conducted: not reported but trial ’initiated’ in 1973
Sources of funding: not reported
Declaration of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Not mentioned, but unlikely to be a prob-
lem in a within-person study
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Treatments are quite different and patients’
perception of treatment may well affect as-
sessment of visual acuity
Blinding of participants and personnel
(performance bias)
Progression of diabetic retinopathy
Unclear risk -
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “ . . . best corrected visual acuities were ob-
tained at each visit, on subjective
testing, by a refractionist who was not aware
of the previous visual acuity nor the treated
eye” Page 557
30Laser photocoagulation for proliferative diabetic retinopathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hercules 1977 (Continued)
Blinding of outcome assessment (detection
bias)
Progression of diabetic retinopathy
Unclear risk -
Incomplete outcome data (attrition bias)
All outcomes
High risk “Eight patients subsequently receiving treat-
ment to the ’control’ eye were removed from
the study at that point.” Page 556
Selective reporting (reporting bias) Unclear risk No access to protocol
Other bias Unclear risk -
Sato 2012
Methods Parallel group RCT. One eye per person enrolled; unclear how eye selected
Participants Country: Japan
Number of participants (eyes): 69 (69)
% women: 25%
Average age: 60 years
Inclusion criteria:
• preproliferative diabetic retinopathy
• no previous photocoagulation
• multiple non perfusion areas larger than one disc area on fluorescein angiography
images
Exclusion criteria:
• clear fluorescein angiography images could not be obtained due to opaque media
• fluorescein angiography could not be performed (e.g. due to allergy)
• past history of intraocular surgery (except if 3 or more years after cataract surgery)
• PRP indicated
Interventions Intervention (n = 32)
• selective photocoagulation of nonperfusion areas
Comparator (n = 37)
• deferred panretinal laser photocoagulation
For the comparator group: “Whenever PDR developed, PRP was performed. The develop-
ment of PDR was defined as the detection of any of the following: neovascularization detected
by ophthalmoscope or FA and preretinal hemorrhage or vitreous hemorrhage. Therefore, in
this study, PDR includes not only high-risk PDR but also early PDR as described by the Early
Treatment Diabetic Retinopathy Study Research Group (ETDRS)” Page 53
In both intervention and comparator groups: “ . . . photocoagulation for macular edema
was permitted when the ophthalmologist in charge of this study considered it necessary”. Page
53/54
Outcomes Primary outcome:
• development of proliferative diabetic retinopathy
Secondary outcomes:
• high risk PDR
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Sato 2012 (Continued)
• severe visual loss (BCVA < 0.025)
• vitreous haemorrhage
Follow-up: 3 years
Notes Date conducted: February 2004-December 2008
Sources of funding: “This study was supported by a Grant-in-Aid for Scientific Research C
(no. 17591856), 2005, from the Japan Society for the Promotion of Science. The following
authors have indicated that they have received grants from the Japanese Government: Sadao
Hori and Naohito Yamaguchi.” Page 59
Declaration of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patient data and FA images in those pa-
tients considered to be appropriate subjects by
the ophthalmologists in charge of this study
at each institution were sent to the Data
Center in the Department of Public Health,
Tokyo Women’s Medical University. At the
Data Center, a designated ophthalmologist
confirmed whether each patient’s data and
FA images were appropriate. After confirma-
tion, the patients were randomly assigned to
either the nonphotocoagulation group (non-
PC group) or to the photocoagulation group
(PC group) using random number tables, and
the ophthalmologists in charge of this study
were informed of the groups into which their
patients had been randomized.” Page 53
Allocation concealment (selection bias) Low risk “Patient data and FA images in those pa-
tients considered to be appropriate subjects by
the ophthalmologists in charge of this study
at each institution were sent to the Data
Center in the Department of Public Health,
Tokyo Women’s Medical University. At the
Data Center, a designated ophthalmologist
confirmed whether each patient’s data and
FA images were appropriate. After confirma-
tion, the patients were randomly assigned to
either the nonphotocoagulation group (non-
PC group) or to the photocoagulation group
(PC group) using random number tables, and
the ophthalmologists in charge of this study
were informed of the groups into which their
patients had been randomized.” Page 53
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Sato 2012 (Continued)
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Not reported and treatments different
Blinding of participants and personnel
(performance bias)
Progression of diabetic retinopathy
Low risk We judged it unlikely that patient or
carer knowledge of treatment assignment
would impact on the progression of dia-
betic retinopathy
Blinding of outcome assessment (detection
bias)
Visual acuity
High risk Not reported and treatments different
Blinding of outcome assessment (detection
bias)
Progression of diabetic retinopathy
High risk Not reported and treatments different
Incomplete outcome data (attrition bias)
All outcomes
High risk “When we discontinued the study in Decem-
ber 2009, the courses of 17 patients (8 in the
non-PC group and 9 in the PC group) had
not yet been observed for the whole 36months,
although these patients could potentially con-
tinue to be observed for the 36 months. Of the
69 patients, 36 (23 in the non-PC group and
13 in the PC group) completed the 36-month
follow-up inDecember 2009. Another 16 pa-
tients (6 in the non-PC group and 10 in the
PC group) had dropped out of the study for
the following reasons: 10 stopped coming to
the hospital, 3 switched hospitals, 1 developed
severe visual loss due to central retinal artery
occlusion, 1 died, and 1 developed an allergy
to fluorescein. As the number of patients who
dropped out of the study was somewhat larger
in the PC than in the non-PC group, we con-
ducted the analysis using the intent-to-treat
method in all 69 patients, as well as the treat-
ment method in 36 patients”. Page 54
Outcomes of relevance to this review were
largely reported on the 36 patients fol-
lowed-up to three years. Development of
PDR was reported in all 69 patients as well
Selective reporting (reporting bias) Unclear risk No access to protocol
Other bias High risk “The study was discontinued in December
2009. An analysis performed in October
2009 revealed a significantly higher incidence
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Sato 2012 (Continued)
of PDR in the non-PC group. Thus, the Data
MonitoringCommittee suggested that contin-
uing the study without providing the results to
the public would be a major disadvantage to
the patients randomized to the non-PC group.
” Page 54
Yassur 1980
Methods Within-person RCT; both eyes included in study, eyes received different treatments
Participants Country: USA
Number of participants (eyes): 45 (90)
% women: 48%
Average age (range): not reported (16-72)
Inclusion criteria: not reported but participants had “neovascularisation of the disc” i.e.
PDR
Exclusion criteria: not reported
Interventions Intervention (n = 45)
• argon laser
Comparator (n = 45)
• no treatment
Outcomes Primary outcome:
• new proliferation on the disc
Follow-up: 4 years
Notes Date conducted: 1973-1974
Sources of funding: not reported
Declaration of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “ . . . only one eye was randomly assigned to
treatment” Page 78
Allocation concealment (selection bias) Low risk Not mentioned, but unlikely to be a prob-
lem in a within-person study
Blinding of participants and personnel
(performance bias)
Visual acuity
Unclear risk -
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Yassur 1980 (Continued)
Blinding of participants and personnel
(performance bias)
Progression of diabetic retinopathy
Low risk We judged it unlikely that patient or
carer knowledge of treatment assignment
would impact on the progression of dia-
betic retinopathy
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk -
Blinding of outcome assessment (detection
bias)
Progression of diabetic retinopathy
High risk Masking not mentioned and treatments
quite different
Incomplete outcome data (attrition bias)
All outcomes
High risk “Initially we reviewed the records of 83 con-
secutive patients assigned for a 4-year follow-
up, but 16 patients dropped out at various
stages because of death, inadequate follow-up,
or because the ’control’ eye was also treated.”
Page 78
Selective reporting (reporting bias) Unclear risk No access to protocol
Other bias Unclear risk -
Abbreviations
BCVA: best corrected visual acuity
DR: diabetic retinopathy
ETDRS: Early Treatment Diabetic Retinopathy Study Research Group
FA: fluorescein angiography
NEI: National Eye Institute
NIH: National institutes for Healh
PDR: proliferative diabetic retinopathy
PRP: panretinal photocoagulation
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Hussainy 2008 No untreated or deferred laser control group
Atmaca 1995 No untreated or deferred laser control group
Bandello 1993 No untreated or deferred laser control group
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(Continued)
Bandello 1996 No untreated or deferred laser control group
Bandello 2001 No untreated or deferred laser control group
Bandello 2012 Not an RCT
Beetham 1969 Laser no longer in use
Birch-Cox 1978 Not RCT
Blankenship 1987 No untreated or deferred laser control group
Blankenship 1989 No untreated or deferred laser control group
Brancato 1990 No untreated or deferred laser control group
Brancato 1991 No untreated or deferred laser control group
British Multicentre Study Group 1975 Laser no longer in use
Buckley 1992 No untreated or deferred laser control group
Canning 1991 No untreated or deferred laser control group
Capoferri 1990 No untreated or deferred laser control group
Chaine 1986 No untreated or deferred laser control group
Chen 2013 No untreated or deferred laser control group
Crick 1978 No untreated or deferred laser control group
Doft 1982 No untreated or deferred laser control group
Doft 1992 No untreated or deferred laser control group
Dong 1997 Not an RCT
Elsner 2005 No untreated or deferred laser control group
Emi 2009 Not an RCT
Fankhauser 1972a No untreated or deferred laser control group
Fankhauser 1972b No untreated or deferred laser control group
Francois 1977 No untreated or deferred laser control group
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(Continued)
Gerke 1985 No untreated or deferred laser control group
Haas 1999 No untreated or deferred laser control group
Hamilton 1981 No untreated or deferred laser control group
Ivanisevic 1992 No untreated or deferred laser control group
KARNS 1988 No untreated or deferred laser control group
Khosla 1994 No untreated or deferred laser control group
Klemen 1985 No untreated or deferred laser control group
Kovacic 2007 No untreated or deferred laser control group
Kovacic 2012 No untreated or deferred laser control group
Li 1986 No untreated or deferred laser control group
Liang 1983 No untreated or deferred laser control group
Lim 2009 Not an RCT
Lopez 2008 No untreated or deferred laser control group
MAPASS 2010 No untreated or deferred laser control group
McLean 1972 Unable to locate reference
Menchini 1990 No untreated or deferred laser control group
Menchini 1995 No untreated or deferred laser control group
Mirkiewicz-Sieradzka 1988 Not an RCT
Mirshahi 2013 No untreated or deferred laser control group
Misra 2013 Not an RCT
Mody 1983 No untreated or deferred laser control group
Muraly 2011 No untreated or deferred laser control group
Nagpal 2010 No untreated or deferred laser control group
Neira-Zalentein 2011 Not an RCT
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(Continued)
Okuyama 1995 No untreated or deferred laser control group
Pahor 1998 No untreated or deferred laser control group
Pahor 1999 Not an RCT
Peng 2013 No untreated or deferred laser control group
Perez 2008 No untreated or deferred laser control group
PETER PAN Study 2013 No untreated or deferred laser control group
Plumb 1982 No untreated or deferred laser control group
Salman 2011 No untreated or deferred laser control group
Schiodte 1983 No untreated or deferred laser control group
Seiberth 1986 Not an RCT
Seiberth 1987 Not an RCT
Seiberth 1993 No untreated or deferred laser control group
Seymenoglu 2013 No untreated or deferred laser control group
Shimura 2003 No untreated or deferred laser control group
Shimura 2009 Not an RCT
Stanga 2010 No untreated or deferred laser control group
Tewari 2000 No untreated or deferred laser control group
Theodossiadis 1990 No untreated or deferred laser control group
Townsend 1980 Laser no longer in use
Uehara 1993 No untreated or deferred laser control group
Vera-Rodriguez 2008 No untreated or deferred laser control group
Wade 1990 No untreated or deferred laser control group
Wiznia 1985 Not an RCT
Wroblewski 1991 No untreated or deferred laser control group
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(Continued)
Wroblewski 1992 No untreated or deferred laser control group
Zaluski 1986 No untreated or deferred laser control group
Abbreviation
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Francois 1971
Methods
Participants
Interventions
Outcomes
Notes Currently unable to source a copy of the article
Gaudric 1987
Methods
Participants
Interventions
Outcomes
Notes Currently unable to source a copy of the article
Guo 2014
Methods
Participants
Interventions
Outcomes
Notes Awaiting a translation of the report of the study
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Kaluzny 1985
Methods
Participants
Interventions
Outcomes
Notes Awaiting a translation of the report of the study
Krill 1971
Methods
Participants
Interventions
Outcomes
Notes Currently unable to source a copy of the article
Leuenberger 1975
Methods
Participants
Interventions
Outcomes
Notes Currently unable to source a copy of the article
Li 1987
Methods
Participants
Interventions
Outcomes
Notes Awaiting a translation of the report of the study
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Lund 1971
Methods
Participants
Interventions
Outcomes
Notes Awaiting a translation of the report of the study
Mella 1976
Methods
Participants
Interventions
Outcomes
Notes Awaiting a translation of the report of the study
Mirzabekova 2004
Methods
Participants
Interventions
Outcomes
Notes Awaiting a translation of the report of the study
Okun 1968
Methods
Participants
Interventions
Outcomes
Notes Currently unable to source a copy of the article
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Pahor 1997
Methods
Participants
Interventions
Outcomes
Notes Awaiting a translation of the report of the study
Palacz 1988
Methods
Participants
Interventions
Outcomes
Notes Awaiting a translation of the report of the study
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D A T A A N D A N A L Y S E S
Comparison 1. Laser photocoagulation versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Loss of 15 or more letters BCVA
at 12 months
2 8926 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.89, 1.11]
2 Loss of 15 or more letters BCVA
at 2 years
2 8306 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.80, 0.97]
3 Loss of 15 or more letters BCVA
at 3 years
2 7458 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.93, 1.23]
4 Severe visual loss (BCVA < 6/60) 4 9276 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.24, 0.86]
5 Progression of diabetic
retinopathy
4 8331 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.37, 0.64]
6 Vitreous haemorrhage 2 224 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.37, 0.85]
Analysis 1.1. Comparison 1 Laser photocoagulation versus control, Outcome 1 Loss of 15 or more letters
BCVA at 12 months.
Review: Laser photocoagulation for proliferative diabetic retinopathy
Comparison: 1 Laser photocoagulation versus control
Outcome: 1 Loss of 15 or more letters BCVA at 12 months
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DRS 1978 (1) 157/752 183/752 35.3 % 0.86 [ 0.71, 1.04 ]
ETDRS 1991 358/3711 336/3711 64.7 % 1.07 [ 0.92, 1.23 ]
Total (95% CI) 4463 4463 100.0 % 0.99 [ 0.89, 1.11 ]
Total events: 515 (Laser), 519 (Control)
Heterogeneity: Chi2 = 3.28, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laser Favours control
(1) Loss of 2 or more lines
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Analysis 1.2. Comparison 1 Laser photocoagulation versus control, Outcome 2 Loss of 15 or more letters
BCVA at 2 years.
Review: Laser photocoagulation for proliferative diabetic retinopathy
Comparison: 1 Laser photocoagulation versus control
Outcome: 2 Loss of 15 or more letters BCVA at 2 years
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DRS 1978 (1) 117/442 159/442 22.4 % 0.74 [ 0.60, 0.90 ]
ETDRS 1991 507/3711 552/3711 77.6 % 0.92 [ 0.82, 1.03 ]
Total (95% CI) 4153 4153 100.0 % 0.88 [ 0.80, 0.97 ]
Total events: 624 (Laser), 711 (Control)
Heterogeneity: Chi2 = 3.65, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 2.62 (P = 0.0088)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laser Favours control
(1) Loss of 2 or more lines
Analysis 1.3. Comparison 1 Laser photocoagulation versus control, Outcome 3 Loss of 15 or more letters
BCVA at 3 years.
Review: Laser photocoagulation for proliferative diabetic retinopathy
Comparison: 1 Laser photocoagulation versus control
Outcome: 3 Loss of 15 or more letters BCVA at 3 years
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ETDRS 1991 358/3711 336/3711 99.6 % 1.07 [ 0.92, 1.23 ]
Sato 2012 (1) 3/13 2/23 0.4 % 2.65 [ 0.51, 13.89 ]
Total (95% CI) 3724 3734 100.0 % 1.07 [ 0.93, 1.23 ]
Total events: 361 (Laser), 338 (Control)
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laser Favours control
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(1) Loss of 2 more lines, follow-up 3 years
Analysis 1.4. Comparison 1 Laser photocoagulation versus control, Outcome 4 Severe visual loss (BCVA <
6/60).
Review: Laser photocoagulation for proliferative diabetic retinopathy
Comparison: 1 Laser photocoagulation versus control
Outcome: 4 Severe visual loss (BCVA < 6/60)
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DRS 1978 (1) 15/818 28/812 30.2 % 0.53 [ 0.29, 0.99 ]
ETDRS 1991 (2) 96/3711 137/3711 39.6 % 0.70 [ 0.54, 0.91 ]
Hercules 1977 (3) 7/94 36/94 26.5 % 0.19 [ 0.09, 0.41 ]
Sato 2012 0/13 1/23 3.8 % 0.57 [ 0.02, 13.10 ]
Total (95% CI) 4636 4640 100.0 % 0.46 [ 0.24, 0.86 ]
Total events: 118 (Laser), 202 (Control)
Heterogeneity: Tau2 = 0.25; Chi2 = 10.10, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laser Favours control
(1) Follow-up: 12 months
(2) Follow-up: 5 years
(3) Follow-up: 3 years
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Analysis 1.5. Comparison 1 Laser photocoagulation versus control, Outcome 5 Progression of diabetic
retinopathy.
Review: Laser photocoagulation for proliferative diabetic retinopathy
Comparison: 1 Laser photocoagulation versus control
Outcome: 5 Progression of diabetic retinopathy
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DRS 1978 (1) 74/373 157/388 37.3 % 0.49 [ 0.39, 0.62 ]
ETDRS 1991 (2) 874/3711 1512/3711 50.6 % 0.58 [ 0.54, 0.62 ]
Sato 2012 (3) 2/13 12/23 3.8 % 0.29 [ 0.08, 1.12 ]
Yassur 1980 (4) 5/45 36/67 8.3 % 0.21 [ 0.09, 0.49 ]
Total (95% CI) 4142 4189 100.0 % 0.49 [ 0.37, 0.64 ]
Total events: 955 (Laser), 1717 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.03, df = 3 (P = 0.05); I2 =63%
Test for overall effect: Z = 5.24 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laser Favours control
(1) Increased severity of one grade or more, follow-up 12 months
(2) Development of high risk retinopathy, follow-up 5 years
(3) Development of proliferative retinopathy, follow-up 3 years
(4) Increased new vessels by one grade or more, follow-up 4 years
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Analysis 1.6. Comparison 1 Laser photocoagulation versus control, Outcome 6 Vitreous haemorrhage.
Review: Laser photocoagulation for proliferative diabetic retinopathy
Comparison: 1 Laser photocoagulation versus control
Outcome: 6 Vitreous haemorrhage
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hercules 1977 24/94 40/94 90.8 % 0.60 [ 0.40, 0.91 ]
Sato 2012 (1) 0/13 5/23 9.2 % 0.16 [ 0.01, 2.61 ]
Total (95% CI) 107 117 100.0 % 0.56 [ 0.37, 0.85 ]
Total events: 24 (Laser), 45 (Control)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laser Favours control
(1) Follow-up: 3 years
A D D I T I O N A L T A B L E S
Table 1. Characteristics of laser photocoagulation
Study Type of laser Type of photo-
coagulation
Number (size) of
burns
Intensity Exposure time
(seconds)
Number of ses-
sions
DRS 1978 Argon Panretinal
Focal treatment
of new vessels
800-1600 (500
µm) or
500-1000 (1000
µm)
Not reported 0.1 1 (usually)
ETDRS 1991 Argon Panretinal Full: 1200-1600
(500 µm)
Mild: 400-650
(500 µm)
Moderate 0.1 Full: 2 or more
Mild: 1
Hercules 1977 Argon Panretinal 800 to 3000 (200
µm and 500 µm)
Minimal retinal
blanching
Not reported Up to 6
Sato 2012 Not reported Selec-
tive photocoagu-
lation of non-per-
fusion areas
(400 µm-500
µm)
Not reported Not reported
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Table 1. Characteristics of laser photocoagulation (Continued)
Yassur 1980 Argon Panretinal As for DRS 1978 As for DRS 1978 As for DRS 1978 As for DRS 1978
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Diabetic Retinopathy] explode all trees
#2 diabet* near/3 retinopath*
#3 proliferat* near/3 retinopath*
#4 diabet* near/3 maculopath*
#5 neovasculari?ation
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Light Coagulation] explode all trees
#8 photocoagulat*
#9 photo next coagulat*
#10 (focal or grid) near/3 laser*
#11 coagulat* or argon or krypton or YAG or diode or micropulse or panretinal
#12 #7 or #8 or #9 or #10 or #11
#13 #6 and #12
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp diabetic retinopathy/
14. (diabet$ adj3 retinopath$).tw.
15. (proliferat$ adj3 retinopath$).tw.
16. (diabet$ adj3 maculopath$).tw.
17. neovasculari?ation.tw.
18. or/13-17
19. exp light coagulation/
20. photocoagulat$.tw.
21. (photo adj1 coagulat$).tw.
22. ((focal or grid) adj3 laser$).tw.
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23. (coagulat$ or argon or krypton or YAG or diode or micropulse or panretinal).tw.
24. or/19-23
25. 18 and 24
26. 12 and 25
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp diabetic retinopathy/
34. (diabet$ adj3 retinopath$).tw.
35. (proliferat$ adj3 retinopath$).tw.
36. (diabet$ adj3 maculopath$).tw.
37. neovasculari?ation.tw.
38. or/33-37
39. exp laser coagulation/
40. argon laser/
41. photocoagulat$.tw.
42. (photo adj1 coagulat$).tw.
43. ((focal or grid) adj3 laser$).tw.
44. (coagulat$ or argon or krypton or YAG or diode or micropulse or panretinal).tw.
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45. or/39-44
46. 38 and 45
47. 32 and 46
Appendix 4. metaRegister of Controlled Trials search strategy
diabetic retinopathy AND (laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode micropulse OR
panretinal)
Appendix 5. ClinicalTrials.gov search strategy
diabetic retinopathy AND (laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode micropulse OR
panretinal)
Appendix 6. ICTRP search strategy
diabetic retinopathy = Condition AND laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode
micropulse OR panretinal = Intervention
Appendix 7. Data extraction sheet on trial characteristics
Table heading in RevMan 2014 Subheadings for CEVG reviews Comment
Methods Trial design Parallel group RCT (i.e. people randomised to treatment)
Paired eye or intra-individual RCT (i.e. eyes randomised to
treatment)
Cluster RCT (i.e. communities randomised to treatment)
Cross-over RCT
Other, specify
Eyes One eye included in trial
- Specify how eye selected
Both eyes included in trial, eyes received same treatment
- Briefly specify how analysed (best/worst/average/both and
adjusted for within-person correlation/both and not adjusted
for within-person correlation)
- Specify if mixture one eye and two eye
Both eyes included in trial, eyes received different treatments
(pair matched)
- Specify if correct pair-matched analysis done
Participants Country
Number of participants
% women
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(Continued)
Average age
Age range
Inclusion criteria
Exclusion criteria
Interventions Intervention
Comparator
Including number of participants randomly allocated to each
Outcomes List Outcomes reported in methods and results, identify primary
outcome if specified
Notes Date conducted Dates of recruitment of participants month/year to month/
year
Sources of funding If reported
Declaration of interest If reported
WH A T ’ S N E W
Last assessed as up-to-date: 3 June 2014.
Date Event Description
7 August 2015 Amended Edits made to the Summary of findings table and additional source of support added
C O N T R I B U T I O N S O F A U T H O R S
JE prepared a first draft of the protocol, which was revised by GV.
JE and MM screened search results and extracted data. GV and MM reviewed and commented on various drafts of the review.
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D E C L A R A T I O N S O F I N T E R E S T
JE: none known
MM: none known
GV: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Italian Ministry of Health and Fondazione Roma, Italy.
The contribution of the IRCCS Fondazione Bietti in this paper was supported by the Italian Ministry of Health and by Fondazione
Roma, Italy
• National Institute for Health Research (NIHR), UK.
• Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision Group (CEVG) acknowledges financial support for
his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre
for Ophthalmology.
• The NIHR also funds the CEVG Editorial Base in London.
• The Cochrane Review Incentive Scheme provided funding for Jennifer Evans to assist with completion of this review.
The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or the Department of
Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Title
On the recommendation of a clinical peer reviewer we changed the title of this review from “laser photocoagulation for diabetic
retinopathy” to “laser photocoagulation for proliferative diabetic retinopathy”. The reviewer felt that clinicians seeing the broader title
would expect to see diabetic macular oedema (DMO) included in this review but this is specifically excluded as there is a separate
review looking at laser for DMO (Jorge 2013).
Outcomes
We changed ’distance corrected near visual acuity’ to ’near visual acuity’. We did not find any data on near visual acuity, either distance
corrected or not.
We moved the outcome ’severe visual loss’ out of adverse effects and further up the list, refecting the use of this outcome generally as a
measure of effect rather than an adverse effect as originally defined in our protocol. We considered this outcome at one year follow-up
as for the other effectiveness outcomes (and not, as originally planned, within three months of treatment).
We removed the outcome ’secondary choroidal neovascularisation’ for future updates. This outcome is more of a concern after treatment
for diabetic macular oedema. We did not find any data on this outcome.
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Measures of effect
We planned to calculate the risk ratio for dichotomous variables where the event risk was greater than 10%, the odds ratio for
dichotomous variables where the event risk was less than 10% and for very rare events (less than 1%) the Peto odds ratio. In fact for
most analyses the event risk in the control group was greater than, or approximately, 10% and we felt that it would be confusing to
report an odds ratio for only one outcome (severe visual loss) where the event rate was 4%. We have therefore only used the risk ratio
as the measure of effect for dichotomous variables. This decision has not affected the conclusions drawn. For the outcome of severe
visual loss the reported risk ratio was 0.46 (95% CI 0.24 to 0.86) and this is similar to the odds ratio of 0.40 (95% CI 0.18 to 0.88).
Data synthesis
We planned that, in cases of substantial heterogeneity, for example differences in direction of effect, or where the I2 statistic was greater
than 50% and the Chi2 statistic less than 0.1, such that the pooled result did not summarize the individual trial results adequately, we
would not provide a pooled estimate, unless visual inspection of the forest plot indicated it might be appropriate to do so (for example,
if all effect estimates were in the same direction). For one analysis, Analysis 1.1, the effect estimates were reasonably close to 1 and we
report a pooled estimate even though the effect estimates were not in the same direction.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Diabetic Retinopathy [∗surgery]; Disease Progression; Laser Coagulation [∗methods]; Randomized Controlled Trials as Topic; Time
Factors; Vision Disorders [etiology]; Visual Acuity; Vitreoretinopathy, Proliferative [∗surgery]; Watchful Waiting
MeSH check words
Humans
53Laser photocoagulation for proliferative diabetic retinopathy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
